LP
RANI icon

Longaeva Partners’s Rani Therapeutics RANI Stock Holding History

Longaeva Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Buy
2,329,459
+216,024
+10% +$276K 0.06% 156
2025
Q4 		$2.85M Buy
+2,113,435
New +$3.19M 0.24% 84

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Longaeva Partners's RANI Position: Q1 2026 in Review

Longaeva Partners increased its Rani Therapeutics (RANI) stake by 10% in Q1 2026, buying an estimated $276K and bringing the position to 2,329,459 shares worth $1.71M. The position accounts for 0.06% of the portfolio, ranked #156.

Longaeva Partners first reported a position in RANI in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.85M in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Longaeva Partners held 2,329,459 shares of Rani Therapeutics worth $1.71M as of Q1 2026.
  • Longaeva Partners bought 216,024 Rani Therapeutics shares in Q1 2026, an estimated $276K.
  • Rani Therapeutics made up 0.06% of Longaeva Partners's portfolio in Q1 2026, its #156 holding.
  • Longaeva Partners first reported a position in Rani Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Longaeva Partners's Rani Therapeutics position peaked at $2.85M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.